% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wattad:124418,
      author       = {M. Wattad and D. Weber and K. Döhner and J. Krauter and V.
                      I. Gaidzik and P. Paschka and M. Heuser and F. Thol and T.
                      Kindler and M. Lübbert and H. R. Salih and A. Kündgen and
                      H.-A. Horst and P. Brossart and K. Götze and D. Nachbaur
                      and C.-H. Köhne and M. Ringhoffer and G. Wulf and G. Held
                      and H. Salwender and A. Benner$^*$ and A. Ganser and H.
                      Döhner and R. Schlenk},
      title        = {{I}mpact of salvage regimens on response and overall
                      survival in acute myeloid leukemia with induction failure.},
      journal      = {Leukemia},
      volume       = {31},
      number       = {6},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-01295},
      pages        = {1306 - 1313},
      year         = {2017},
      abstract     = {We evaluated the impact of salvage regimens and allogeneic
                      hematopoietic cell transplantation (allo-HCT) in acute
                      myeloid leukemia (AML) with induction failure. Between 1993
                      and 2009, 3324 patients with newly diagnosed AML were
                      enrolled in 5 prospective treatment trials of the
                      German-Austrian AML Study Group. After first induction
                      therapy with idarubicin, cytarabine and etoposide (ICE), 845
                      patients had refractory disease. In addition, 180 patients,
                      although responding to first induction, relapsed after
                      second induction therapy. Of the 1025 patients with
                      induction failure, 875 (median age 55 years) received
                      intensive salvage therapy: 7+3-based (n=59), high-dose
                      cytarabine combined with mitoxantrone (HAM; n=150), with
                      all-trans retinoic acid (A; A-HAM) (n=247), with gemtuzumab
                      ozogamicin and A (GO; GO-A-HAM) (n=140), other intensive
                      regimens (n=165), experimental treatment (n=27) and direct
                      allo-HCT (n=87). In patients receiving intensive salvage
                      chemotherapy (n=761), response (complete remission/complete
                      remission with incomplete hematological recovery (CR/CRi))
                      was associated with GO-A-HAM treatment (odds ratio (OR),
                      1.93; P=0.002), high-risk cytogenetics (OR, 0.62; P=0.006)
                      and age (OR for a 10-year difference, 0.75; P<0.0001).
                      Better survival probabilities were seen in an extended Cox
                      regression model with time-dependent covariables in patients
                      responding to salvage therapy (P<0.0001) and having the
                      possibility to perform an allo-HCT (P<0.0001). FLT3 internal
                      tandem duplication, mutated IDH1 and adverse cytogenetics
                      were unfavorable factors for survival.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28138160},
      doi          = {10.1038/leu.2017.23},
      url          = {https://inrepo02.dkfz.de/record/124418},
}